Big Pharma’s Patent Cliffs
July 18, 2024
No Comments
EY estimates that the top twenty biopharma companies have $180 billion in sales at risk from patent expirations between now and 2028. Why isn’t their widespread panic at big pharma’s patent cliffs?! What is a